Drug Profile
AGS 67E
Alternative Names: AGS67ELatest Information Update: 14 Dec 2017
Price :
*
At a glance
- Originator Agensys
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia; Lymphoid leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 11 Dec 2017 AGS 67E is still in phase I trials for Lymphoid leukaemia, Hairy cell leukaemia, Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA and Canada (Astellas Pharma pipeline, December 2017)
- 30 Nov 2017 Agensys suspends patient enrolment in a phase I trials due to business decision by sponsor for Acute myeloid leukaemia (Second-line therapy or greater) in USA, Canada (IV) (NCT02610062)
- 30 Nov 2017 Agensys suspends patient enrolment in a phase I trials due to business decision by sponsor for Lymphoid leukaemia, Hairy cell leukaemia, Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA and Canada (IV) (NCT02175433)